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Cancer stem cells with stem-cell properties are regarded as tumor initiating cells.
Sharing stem-cell properties, circulating tumor cells (CTCs) are responsible for the
development of metastasis, which significant affects CTC analysis in clinical practice.
Due to their extremely low occurrence in blood, however, it is challenging to enumerate
and analyze CTCs. Nanotechnology is able to address the problems of insufficient
capture efficiency and low purity of CTCs owing to the unique structural and functional
properties of nanomaterials, showing strong promise for CTC isolation and detection.
In this review, we discuss the role of stem-like CTCs in metastases, provide insight into
recent progress in CTC isolation and detection approaches using various nanoplatforms,
and highlight the role of nanotechnology in the advancement of CTC research.
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isolation and detection
INTRODUCTION
Tumors are heterogeneous tissues composed of abundant phenotypically and functionally distinct
cell subpopulations each having different capacities to grow, differentiate, develop drug resistance
and form metastases. Stem cell properties, including self-renewal, the capability to develop into
multiple lineages, and the potential to proliferate extensively, play critical roles in the generation
of complex multicellular organisms. A growing body of evidence suggests that stem cell properties
are relevant to some forms of human cancer, and cells with these properties are involved in tumor
metastasis and drug resistance (Fang et al., 2005). Cancer cells sharing stem cell properties are called
“cancer stem cells” (CSCs). CSCs are intrinsically drug resistant and often evade chemotherapies,
and they eventually induce tumor relapses or metastases (Malanchi et al., 2012). During metastatic
dissemination, circulating tumor cells (CTCs) invade distant organs and settle in supportive niches
(Pantel et al., 2009). In this process, the stem cell-like properties within CTCs contribute to
CTC survival and eventually seed the growth of a secondary tumor. It is documented that high
CTC numbers indicate poor prognosis even after effective radiotherapies and chemotherapies.
Monitoring CTC levels may aid in predicting the response to ongoing therapy and developing
personalized medicine.
Based on these considerations, the CTC enumeration and detection shows great clinical value,
and their prognostic significance has been demonstrated in several types of cancers, including
breast, prostate, colon, melanoma, and lung cancer (Masuda et al., 2016). However, due to extreme
rarity, it is challenging to detect and analyze CTCs. Therefore, an ideal technology with great
efficiency and sensitivity, which can also release and collect captured CTCs with a high vitality,
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FIGURE 1 | Metastatic colonization based on circulating tumor stem cells. Metastasis proceeds through multiple steps that occur in two major phases: (i) the
pre-colonization phase of metastasis comprises physical translocation of cancer cells from the primary tumor to the circulation and (ii) the colonization phase after
circulating tumor cell (CTC) extravasation. Cancer cells within the primary tumor undergo an epithelial-mesenchymal transition (EMT) process and endow invasive
capacity, then intravasate into the tumor vasculature in the form of CTCs, which must be able to survive in the circulating blood and evade from the innate immune
response and other defenses. Once CTCs home to a secondary site, the settlement in supportive niches enables them to survive and retain their stem-like
tumor-initiating capacity. These cancer cells then enter a latent state lasting from months to decades while they adapt to their newfound microenvironment. When
this latency is broken out, the cancer cells reinitiate overt outgrowth and overtake the local tissue microenvironment to commence the coming colonization.
should be developed for CTC studies. To date, a vast number of
isolation and detection techniques have been developed based on
the inherent properties of CTCs (big size, for example), but none
of the methods are perfect because of issues of insufficient capture
and low purity. The development of a better method of detection
and treatment of the rare and important CTCs is desirable.
During the last decades, nanotechnologies have been rapidly
developed, and examples of nanotechnology-based approaches
to improve CTC detection have accumulated. A variety of
advanced nanomaterials have been applied to CTC enrichment
and detection, such as nanoparticles. With the large surface-
to-volume ratio, nanomaterials enable highly efficient cellular
binding in the complex blood matrix. In addition, CTCs naturally
prefer nanostructural surfaces due to their similar scales on the
surface of cells. Furthermore, nanomaterials functionalized with
antibodies can enhance CTC capture efficiency and specificity. In
this review, we discuss the role of stem-like CTCs in metastases.
We then provide insight into recent progress on CTC enrichment
and detection approaches using various nanoplatforms and
highlight the role of nanotechnology in the advancement of CTC
research.
CIRCULATING TUMOR CELL THEORY
The blood of many patients with advanced primary carcinomas
contains CTCs, which can transit to distant organs to form
future metastases after adaptation and proliferation. These CTCs
are the cells sloughing from the edges of a primary tumor
mass and intravasating to enter hematogenous circulation or the
lymphatic system, and can remain loose in circulation, cluster
together as they travel, or lodge themselves in new tissues
(Williams, 2010). Since in 1869, CTCs were first detected in
cancer patients, and the studies on the role of CTCs in cancers
are attractive. It was demonstrated that the presence of five
or more CTCs (breast, prostate, and lung cancer), and three
or more CTCs (colorectal cancer) per 7.5 mL of peripheral
blood caused a shorter median progression-free survival and
shorter overall survival, suggesting that the number of CTCs
before treatment is an independent predictor of progression-free
survival and overall survival (Cristofanilli, 2004). Therefore, it
can be concluded that high CTC numbers are closely correlated
with increased tumor aggressiveness (Pavese and Bergan, 2014)
and metastasis (Cohen et al., 2008; de Bono et al., 2008),
which lead to poor prognosis even after effective radiotherapies
and chemotherapies. Recently, scientists have generated patient-
derived xenograft experimental models of breast (Baccelli et al.,
2013), lung (Hodgkinson et al., 2014), and prostate cancer
(Williams et al., 2015) by using CTCs, demonstrating the tumor-
initiating capacity of CTC in metastasis. CTCs create a successful
metastatic deposit involving a cascade of linked sequential
steps: once lodged in a foreign tissue, CTCs may invade the
local host tissue, survive to proliferate, and eventually seed a
secondary colony (Figure 1). Thus, the proliferative and self-
renewal abilities, which are regarded as the main stem cell-like
properties, are critical for CTCs to facilitate tumor metastasis
in foreign tissues. It was validated that stem cell markers are
frequently overexpressed in CTCs, and therefore, metastasis may
be evoked by subpopulations of CTCs that express CSC markers
(Aktas et al., 2009). These CTCs with stem cell-like properties are
considered as a “seed” for secondary tumors.
As a source of metastatic cells, CTCs could become not only
a potent prognostic marker to indicate therapy effectiveness or
necessity even in the absence of detectable metastases but also an
integral part of tumor staging criteria which are currently focused
on the primary tumor (Cristofanilli et al., 2005; Pierga et al.,
2012). Moreover, CTCs coming from cancer patients provide an
opportunity to study patterns of drug susceptibility (Yu et al.,
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2014), indicating that it may be a novel potential target for tumor
treatment. In light of these considerations, as well as the simple
and minimally invasive process of blood collection, CTC analysis
could be used as a real-time “liquid biopsy” for patients with
cancer. However, there are significant technical challenges that
impede CTC isolation and detection owing to the rarity of CTCs
in blood. Therefore, a better understanding of CTCs may make
their clinical use more applicable.
The Stem Cell-Like Properties within
CTCs
Cancer stem cells are malignant cells with the capacity of self-
renewal, the potential to develop into any cell in the overall
tumor population, and the proliferative ability to drive continued
expansion of the population of malignant cells (Jordan et al.,
2006). It is widely accepted that CSCs play a critical role in cancer
initiation, progression, recurrence, and metastasis (Nguyen et al.,
2012; Shi et al., 2013). CSCs, possessing elevated tumor-initiating
ability (Pattabiraman and Weinberg, 2014), can be identified by
biomarkers (regarded as stem-like markers) including epithelial
cell adhesion molecule (EpCAM), CD44, CD24, CD133, and
aldehyde dehydrogenase (ALDH), etc. (Ajani et al., 2015; Lu et al.,
2016). Moreover, CSCs display the ability to self-renew, which
is often implicated in several signaling pathways, such as Wnt,
Notch, and Hedgehog (Hh) signaling pathways (Takebe et al.,
2011).
Evidence for stem-like CTCs existence was convincingly
documented based on the expression of stem cell markers in
CTCs (Table 1). ALDH1 is a classical stem cell marker that is
frequently expressed in CTCs from patients with breast cancer
(Reuben et al., 2011; Kasimir-Bauer et al., 2012), pancreatic
cancer (Ting et al., 2014), and lung cancer (Hanssen et al.,
2016). Theodoropoulos et al. (2010) showed that 35.2% of CTCs
in metastatic breast cancer patients had the CD44+/CD24−/low
phenotype, which is highly associated with stemness and
tumorigenic potential. CD133, an identified CSCs indicator, was
overexpressed in CTCs and contributed to resistance to cancer
therapies in breast cancer (Nadal et al., 2013) and colorectal
cancer (Iinuma et al., 2011). Schölch et al. (2016) reported
that the stem cell marker Bmi1 was significantly upregulated in
CTCs, suggesting that CTCs possess a stem cell-like phenotype
and an increased capacity of self-renewal and tumor formation.
Moreover, EpCAM, which is considered a CSC marker, is often
expressed in CTCs and commonly used for their enrichment
and detection. Furthermore, the tumor-initiating capacity of
CTCs was proven through xenografts from freshly isolated
CTCs. Hodgkinson et al. (2014) enriched EpCAM+cytokeratin+
CTCs from the blood of small-cell lung cancer (SCLC) patients
and subcutaneously injected them into immunocompromised
mice to form palpable tumors within 4 months. Blood
samples from metastatic breast cancer patients were depleted of
hematopoietic cells and transplanted into the femoral medullar
cavity of immunocompromised mice to test whether CTCs
are tumorigenic. Within 6–12 months after transplantation,
EpCAM+CD44+CD47+MET+ CTCs developed multiple bone,
lung, and liver metastases in mice (Baccelli et al., 2013). In
addition, a xenograft model was successfully generated with
CTCs from isolated prostate cancer patients (Williams et al.,
2015).
CTCs and Metastasis
Due to shed off from primary tumors followed by intravasation
into the circulation system, cancer cells with stem-like properties
performed as circulating tumor stem cells (CTSC) (Clevers, 2011)
(Figure 1). In the early steps of the metastatic cascade, CTCs
have been thought to be involved the epithelial-mesenchymal
transition (EMT) process (Aceto et al., 2014), which leads
epithelial cells to weaken their cell–cell adhesion and gain
migratory and invasive properties, thus becoming mesenchymal-
like cells (Ksia˛z˙kiewicz et al., 2012). Once induced in cancer
cells, EMT may allow them to escape from the primary
tumor, invade into the circulation, and reach the site of
future metastasis (Krawczyk et al., 2014). Upon arriving at
their destinations, the interactions between such CTCs and the
local microenvironment or “niche” modulate tumor metastatic
colonization (Li et al., 2007). The survival and stemness of CTCs
TABLE 1 | Stem cell markers in CTCs of cancer patients.
Marker Type of cancer No. of patients Marker expressed (%) Analytical methodology Reference
EpCAM Breast cancer 24 83.3%∗ Flow cytometry Hyun et al., 2016
Head and neck cancer 15 40%∗ CellSearch system Nichols et al., 2012
ALDH Breast cancer 92 46%∗ AdnaTest Kasimir-Bauer et al., 2012
Colorectal cancer 27 33%∗ PCR Gazzaniga et al., 2010
Breast cancer 24 54%# RT-PCR Barrière et al., 2012
CD133 Breast cancer 23 30.1%# Triple fluorescence Bock et al., 2015
Prostate cancer 20 100%∗ Flow cytometry Nadal et al., 2013
CD44 Colorectal cancer 150 40%∗ RT-PCR Katoh et al., 2015
Breast cancer 24 33%# RT-PCR Barrière et al., 2012
CD24−/low Breast cancer 20 35.2%# Immunofluorescence microscopy Theodoropoulos et al., 2010
Bmi1 Lung cancer 10 70%∗ RT-PCR Ana et al., 2016
Breast cancer 24 67%# RT-PCR Barrière et al., 2012
∗Among CTC positive patients; #among CTCs captured from patients.
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can similarly benefit from interactions with supportive niches,
which are rich in developmental and self-renewal signals, such
as Hh, Wnt, and Notch (Massagué and Obenauf, 2016). Factors
secreted by stromal cell can also influence the stem cell niche,
providing a suitable microenvironment for cancer initiation and
development. For example, breast carcinoma clones are primed
for metastasis in the CXCL12-rich microenvironment of the bone
marrow (Zhang et al., 2013), while bone morphogenic proteins
(BMPs) can induce CD133+ CSCs to differentiate and markedly
attenuate the tumor-forming ability of CD133+ cells (Visvader
and Lindeman, 2008). Due to protection by the niche, cancer cells
are able to adapt to the microenvironment, initiate proliferation
and eventually seed a successful metastasis. Finally, CTCs
usually undergo a process of mesenchymal epithelial transition
(MET) and recover their epithelial character to proliferate and
differentiate into different secondary or metastatic tumors (Nieto,
2013). EMT is now known to not only facilitate the metastatic
spread and the progression of cancer cells (Mitra et al., 2015),
but also to support the induction of a stem cell phenotype with
properties such as self-renewal associated with high invasiveness
and resistance to apoptosis and therapy (Mani et al., 2008).
Stem-like CTCs may proliferate as tumor-initiating cells to form
aggressive tumors during relapse/metastasis.
CTC Characterization
Circulating tumor cells often occur at very low concentrations
in the blood, with estimates of just one CTC per ∼107 white
blood cells (WBCs) per milliliter of blood, suggesting that any
assay for CTC enumeration must be able to handle many
surrounding/normal cells and the error rates will be high.
Therefore, the different properties of CTCs that distinguish
them from the surrounding normal hematopoietic cells can be
utilized for their enrichment and detection. Generally, CTCs
have large size distributions of 20∼30 µm in diameter, which
is much larger than that of capillary bores (∼8 µm) (Chaffer
and Weinberg, 2011). However, their physically plastic properties
facilitate the pass of CTCs into circulation, and indeed CTC
clusters can rapidly and reversibly reorganize into single-file
chain-like geometries and transit through capillary-sized vessels
(Au et al., 2016). In addition, CTCs can be cloaked by platelets
or by coagulation factors to protect themselves from the immune
system and oxidative stress (Labelle et al., 2011; Le et al., 2015).
Thus, it is extremely difficult to accurately detect CTCs. However,
CTC-based biomarkers provide useful approaches for capturing
and detecting CTCs.
EpCAM frequently overexpressed on the surface of CTCs
can be used as a cell biomarker (Maetzel et al., 2009; Huch
and Dollé, 2016). It has demonstrated that CTCs show a high
level of expression of EpCAM in numerous human malignancies
(Went et al., 2006; Barsan et al., 2013). Yamashita et al.
proved that EpCAM+ CTCs are an independent risk factor for
HCC recurrence (Yamashita et al., 2013; Zhou et al., 2016).
Consequently, anti-EpCAM is usually used for CTC screening.
However, EpCAM is expressed in not all tumors, and absent
EpCAM expression has been cited as a reason for the lack of CTC
capture (Khan et al., 2011; Mikolajczyk et al., 2011). In addition,
cytokeratins (CKs), including CK8, CK18 and CK19, are largely
associated with CTCs, and fluorescent anti-CKs antibodies are
often used to recognize and mark CK-positive cells.
Current Advances in the Isolation of
Circulating Tumor Cells
Certainly, CTCs can provide an ideal approach to strongly
affect cancer diagnosis and treatment strategies. Therefore, the
detection of CTCs in blood samples is becoming one of the
most active areas of translational cancer research. To improve
the detection efficiency and speed, various sophisticated systems
have been developed, which generally rely on the different
properties and characteristics between WBCs and CTCs within
the blood (Ee et al., 2016). Currently, methods based on physical
properties, antibodies and nucleic acid are used to isolate and
detect CTCs from whole blood samples. For instance, the large
size, mechanical plasticity and dielectric properties of CTCs
may endow their significant distinction compared with normal
cells (Gascoyne and Shim, 2014; Sollier et al., 2014; Park et al.,
2016). These physical properties are logically utilized for the
isolation and enrichment of CTCs which are fast, simple and
label-free; however, these methods are restricted by their non-
specificity, which can be overcome by an antibody-combined
method (Arya et al., 2013). Antibody-based functional assays
include immunocytochemistry, immunomagnetic, and adhesion-
based methods. Presently, the CellSearch assay, involving
an immunomagnetic technique and image cytometry, is the
only FDA-approved CTC diagnostic technology for metastatic
breast, prostate, and colorectal cancer (de Wit et al., 2014).
The sensitivity and specificity of markers are critical for the
efficiency of such techniques, although none of the markers
are expressed exclusively. Thus, two or more main approaches
can be generally envisioned for this purpose. In nucleic
acid-based approaches, CTCs can be detected using DNA-
or RNA-based technologies with impressive sensitivity. For
example, AdnaTest kits (AdnaGen, Germany), which utilize the
technique of multiplex reverse transcription PCR (RT-PCR),
allow simultaneous amplification and detection of multiple
transcripts of circulating DNA or RNA (Markou et al., 2011).
Additionally, several other methods, such as microscopy imaging,
CTC filters, acoustic-based separation, etc., are available to
detect CTCs (Zheng et al., 2011; Lopez-Riquelme et al., 2013;
Li et al., 2015). Even though there are various approaches
that have been developed for the detection of CTCs, none are
ideal to meet the application needs, as issues of CTC loss, low
purity, and narrow detection spectrum still need to be addressed
(Viswanath and Kim, 2016). Most of these methods contain
a series of complicated processes, such as erythrocyte lysis,
cell centrifugation and washing, which may lead to insufficient
capture and even a waste of detection time and money. Overall,
because of the extreme rarity of CTCs and inadequate sensitivity
and specificity, CTC detection and enumeration is still not a part
of routine tumor staging in clinical practice.
The challenge of CTC detection is related to the requirement
of high sensitivity combined with high specificity (Paterlini-
Brechot and Benali, 2007), however, several factors still hinder the
analysis of CTCs which can be summarized as: (i) CTCs are very
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rare in the circulation, (ii) there is no marker that can reliably and
efficiently distinguish these CTCs from other blood-borne cells
(Esmaeilsabzali et al., 2013) and (iii) downstream molecular and
genomic characterization are challenging due to the low number
of cells that can be isolated (Friedlander et al., 2014). To date,
the CTC analysis techniques should be urgently developed with
high sensitivity and selectivity, which can also be used for the
rapid purification of CTCs, paving the way for downstream CTC
characterization, and obtaining viable CTCs for ex vivo expansion
(Lin et al., 2014). Currently, nanotechnology provides extensive
applications in biology and medicine, and many researchers
take advantage of nanotechnology to improve the efficiency
and sensibility of CTC capture and to accelerate detection
speed. Nanomaterials possess many unique and excellent physical
properties that can be used to overcome the limitations of
traditional CTC detection methods and make viable CTCs more
accessible.
NANOTECHNOLOGY IN CTCS
Nanotechnology has made excellent contributions to tackle
oncology over the past several decades. The uniquely appealing
features of nanotechnology for drug delivery, diagnosis and
imaging facilitate its application in cancer (Shi J. et al., 2016). For
example, nanoparticles possess greater surface areas and more
functional groups that can be linked with multiple diagnostic
and therapeutic agents (He L. et al., 2016). In cancer therapy,
nanotechnology has enabled the development of targeted drug
delivery, enhanced the properties of therapeutic molecules, and
sustained or stimulus-triggered drug release (Shi S. et al., 2016).
In addition, the development of tumor-targeted contrast agents
based on nanotechnology may offer enhanced sensitivity and
specificity for in vivo tumor imaging, which is able to detect
solid tumors, determine recurrence, and monitor therapeutic
responses (Wang et al., 2008).
Despite being perceived as one of the most promising
developments in the treatment of cancer, nanotechnology
in the detection and therapy of CTCs leaves plenty of
room for improvements, especially for the targeting ability.
Nanotechnology offers a fundamental advantage for early
detection, accurate diagnosis, and personalized treatment of
malignant tumors. In CTC isolation and detection, it can
predominantly improve their efficiency and sensitivity. Also,
nanotechnology can carry drugs and provide approaches for CTC
target treatment. In this review, we would provide insight into
recent advances in CTC detection and therapy achieved through
nanotechnology applications.
Nanomaterials may provide access to improve the enrichment
of extremely scarce CTCs, making the counting and analyzing
of CTCs more precise (Xiong et al., 2016). For instance,
with the advantage of facilitating of cellular internalization,
magnetic nanoparticles (MNPs) can be utilized to enrich
and detect cancer cells under magnetic microarray condition.
Nanoroughened surfaces, as well as nanopillars, nanowires,
and nanofibers, possess large specific surface areas that can
increase interactions with extracellular features. In addition,
carbon nanotubes (CNTs) and graphene oxide (GO) can enable
electrical conductivity to access sensing functionality (Yoon
et al., 2014). More importantly, a certain number of CTCs
are known to be lost due to the lack of specificity in these
methods. Therefore, nanomaterials functionalized with various
antibodies were carried out to target CTCs. EpCAM antigen is
frequently used as a target for CTC enrichment, as it was widely
expressed on the cell surface of CTCs derived from carcinomas
and not detected on blood cells (Allard and Terstappen, 2015).
With the rapid development of technology, the combination
of nanotechnology with these specific antigens will provide
promising approaches for CTC isolation and enumeration.
Immunomagnetic Nanobeads
Immunomagnetic technology is used extensively in CTC
enrichment and detection, because it is easy to manipulate
and exhibits high capture efficiency and specificity. Based on
antibody-antigen binding, immunomagnetic technologies have
good sensitivity that makes it especially suitable for rare CTC
separation. Additionally, in immunomagnetic assays, a magnetic
field can be introduced without direct contact with cells and
attract cells over a broader spatial domain (Chen et al., 2013).
Thus far, various types of immunomagnetic technologies for CTC
separation have been invented. In the earlier stage, magnetic
particles (microbead) were in range more than 0.5 µm, while
MNPs emerged with a smaller diameter in 5–200 nm (Bhana
et al., 2015). MNPs commonly composed of magnetic elements,
such as cobalt (Co) and iron (Fe), show alignment of their
magnetic moment in the presence of magnetic field. MNPs reveal
higher cellular binding capability and excellent stability in whole
blood. Their smaller size makes the attachment to CTCs with
many MNPs easy and leads to a higher magnetic susceptibility.
Furthermore, MNPs with various biomarkers can be exploited to
characterize CTCs.
CellSearch system, a commercially available device for CTC
detection, uses Fe3O4 MNPs coated with anti-EpCAM antibody
to confer magnetic properties to the EpCAM positive cells,
resulting in magnetic separation of CTCs from the bulk of
other cells in the blood (Truini et al., 2014). The CellSearch
system can enumerate CTCs as low as two CTCs in 7.5 mL
of peripheral blood (Allard et al., 2004). MNPs functionalized
with anti-EpCAM antibodies were used to bind selected cells
in the presence of a magnetic field in a reversibly bonded
nanotextured polydimethylsiloxane (PDMS) chamber using
NdFeB block magnets (Hoshino et al., 2011). Kim et al. (2013)
presented a microseparator for the isolation of CTCs using
immunomagnetic nanobeads with bound EpCAM antibodies,
revealing that the CTC microseparator isolated approximately
90% of spiked CTCs in human peripheral blood and purified to
approximately 97%. In another micromagnet array, which was
fabricated integrating inkjet-printing technology combined with
immunomagnetic microchip, the whole blood sample is labeled
with MNPs and separated due to the magnetic momentum when
the mixture flows through the microchannel (Figure 2A) (Chen
et al., 2015). Immunomagnetic nanospheres (IMNs) fabricated
by a convenient and highly controllable layer-by-layer assembly
method successfully captured more than 94% of tumor cells in
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FIGURE 2 | Various nanotechnologies utilized for isolation and detection of CTCs. Different nanotechnologies, such as magnetic nanoparticles (MNPs),
nanostructured substrates and/or combine with a microfluidic chip, are developed for effective and specific isolation and detection of CTCs. (A) Immuno-magnetic
microchip for the detection of CTCs labled with MNPs, which pre-functionalized with anti-epithelial cell adhesion molecule (anti-EpCAM) (Chen et al., 2015). (B) A
nanostructured coating contained nanoparticle can detect and release CTCs from peripheral blood (Eduardo et al., 2015). (C) An aptamer-grafted silicon nanowire
substrate (SiNS) covered by a polydimethylsiloxane (PDMS) chaotic mixer is exploited as a microfluidic CTC chip (Zhao et al., 2016).
whole blood via only a 5 min incubation (Wen et al., 2014).
These efforts of using immunomagnetic nanotechnology as a
CTC capture platform promoted their potential use in clinic.
Meanwhile, criticism is often expressed regarding the fact that
detecting only EpCAM+ cells via this platform would miss some
EpCAM− CTCs and yield a false negative detection (Andree
et al., 2015).
Nanostructured Substrates
Nanoscale components present in the tissue microenvironment,
including the extracellular matrix (ECM) and cell-surface
structures, have been documents. Due to their mutual scale as
a fundamental asset, nanostructured substrates with nanoscale
topography that mimic the natural ECM or basement membrane
can effectively interact with cell surface components. The major
feature of nanostructured substrates is their larger biomimetic
surface area. This feature not only enhances the interaction
between substrates and cell surface targeting but also benefits
the isolation and detection of CTCs (Wang et al., 2013).
Furthermore, nanostructured substrates can be coated with
higher densities of ligand and then increase the binding affinity
to cells (Bhana et al., 2015). Therefore, nanostructured substrates
with improved enrichment and detection accuracy may be
developed as promising bio-platforms for CTC detection.
Various nanostructure substrates have been employed for CTC
detection, including nanopillars (Wang et al., 2011), nanowires
(Shen et al., 2013), nanofilms (Wang et al., 2016), nanocoatings
(Figure 2B) (Eduardo et al., 2015), and PDMS (Islam et al.,
2015), etc. Silicon nanopillars (SiNP) with diameters in the
range of 100–200 nm on a silicon wafer have been used for
cancer cell isolation, and the capture yield of MCF-7 cells
in culture medium was 45–65% on SiNP; 10 times more
than what was achieved on flat silicon (Wang et al., 2009).
Tseng and colleagues pioneered a concept of “NanoVelcro”
cell-affinity substrates, in which CTC capture agent-coated
nanostructured substrates were utilized to immobilize CTCs
with a high efficiency. Generations of NanoVelcro CTC chips
based on silicon nanowire substrate (SiNS) were developed
with a high CTC capture efficiency (Wang et al., 2011; Liu
and Wang, 2014; He W. et al., 2016). The thermoresponsive
NanoVelcro chip was created by grafting thermo-responsive
polymer brushes [poly (N-isopropylacrylamide), PIPAAm] onto
SiNS and incorporating with an overlaid PDMS chaotic mixer.
This chip can increase the contact frequency between CTCs and
NanoVelcro substrates, as well as the capture and release of CTCs
with fast temperature responsiveness at 37 and 4◦C, respectively
(Ke et al., 2015). Furthermore, the CTCs can be purified and
subjected to amplifications of their genomic DNA. Recently,
a degradable zinc-phosphate-based hierarchical nanosubstrate
(HZnPNS) (400–800 nm) emerged for the capture and release of
CTCs (Shan et al., 2016). HZnPNS was functionalized with anti-
EpCAM antibody and detected 6–75 CTCs/mL from metastatic
cancer patient blood samples, which outperformed CellSearch
system (1–125 CTCs/7.5 mL). In addition, HZnPNS allowed
88 ± 4% of captured cells to be gently released with a high
viability of 92 ± 1%. Although nanostructured substrates can be
used as an ultrasensitive tool for enriching rare CTCs from blood
samples and keeping most captured cells viable for subsequent
molecular analysis, further testing on clinical samples is necessary
before reaching conclusions. There is still a challenge for
purification platforms to pave the way for subsequent molecular
and functional analysis.
Incorporation of Nanostructures in
Microfluidics
Microfluidics, another recent technological development, can
also improve the capabilities of CTC capture and detection. In
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microfluidics systems, low volumes of fluids are processed to
achieve multiplexing capabilities and high-throughput screening
(Volpatti and Yetisen, 2014). Taking advantage of small sample-
volume requirements, fast processing times and large surface
areas, various microfluidic platforms have been developed
for rare CTC capture and enrichment (Hajba and Guttman,
2014). Various cell separation mechanisms have been devised
in microfluidic platforms, including mechanisms that rely
on magnetic forces, affinity chromatography, size and/or
deformability-based isolation, and dielectrophoresis (Peng et al.,
2013). Microfluidic technology is of great promise for detecting
viable CTCs with satisfactory efficiency and purifying CTCs for
down-stream biology analyses (Trifanny et al., 2016).
Recent progresses in nanotechnology have aided the
development of advanced CTC-detecting microfluidic devices
for the recovery and purification of CTCs. Immunomagnetic
assays are often combined with microfluidic technology to enrich
and detect CTCs. MNPs are commonly used to label target
tumor cells. When blood sample flows through the microchannel
on top of an array of permanent magnets, nanoparticle-labeled
cells can be separated and captured on the substrate of the
microchannel. The average capture rates for SkBr3, PC3, and
Colo205 cells were 97, 107, and 94%, respectively (Huang et al.,
2013). A nanoelectronic microfluidic chip fabricated by silicon
nanograss (SiNG) electrodes was developed for the label-free
distinguishing of both epithelial and mesenchymal CTCs
(Hosseini et al., 2016). This system showed a great preference
for MCF-7 and MDA-MB231 cancer cells with high capture
yields between 92 and 97%. In another recent report, SiNS was
embedded in the microfluidic chip (Figure 2C) in the combined
use of rationally designed aptamer cocktails to achieve enhanced
and differential capture of CTCs from non-small cell lung cancer
(NSCLC) patients through a synergistic effect (Zhao et al., 2016).
Kwak et al. (2017) utilized MNPs functionalized with anti-
EpCAM antibodies to integrate the surface of the Mag-Gradient
Chip based on microfluidics. The simple and multi-functional
Mag-Gradient Chip can isolate 3 mL of heterogeneous CTCs
sample in 1 h and realize 95.7% EpCAM-positive and 79.3%
EpCAM-negative CTC isolation (Kwak et al., 2017). Although
advances in microfluidic technologies are likely to accelerate
CTC detection, many challenges hinder the clinical applications
of CTC technologies.
Nanotechnology in Stem-Like CTC
Detection
CD44, which generally acts as a cell surface hyaluronic acid (HA)-
binding glycoprotein, is frequently exploited to target CSCs.
Prospectively, CD44 has also been investigated to identify stem-
like CTCs. Galanzha et al. (2009) developed a photoacoustic
(PA) and photothermal (PT) flow cytometry platform for in vivo
detection and killing of CTCs with a stem-like phenotype
(CD44+ CTCs). MNPs functionalized with anti-CD44 were
used to bind and capture the stem-like CTCs under a magnet,
and golden CNTs (GNTs) conjugated with anti-CD44 were
exploited to kill the stem-like CTCs at a low confluence.
Magnetic-induced clustering of MNPs within single cell, yielded
6.6-fold enhanced PT signals compared to the intact area
before magnetic action. Then, the PT technique was applied
to demonstrate ablation of the CD44+ CTCs labeled by GNT-
CD44, confirmed by cell membrane damage and changed in
the optical and fluorescent images. Recently, Hong et al. (2016)
reported a multifunctional magnetic nanowire (NW) offering a
significant improvement in CTC isolation efficiency. On these
magnetic NWs, five different types of antibodies, including DAPI,
anti-EpCAM, anti-CD44, anti-vimentin, and anti-CD45, were
employed to differentiate CTCs from the surrounding leukocytes.
In particular, anti-CD44 was employed to capture CTCs with
stem-like properties. Furthermore, anti-CD44, combining anti-
EpCAM, anti-Keratin18, and anti-insulin-like growth factor
antigen (anti-IGF-I), was also used to functionalize silver-
coated gold nanorods (AuNR/Ag) as surface-enhanced Raman
scattering (SERS) multispectral contrast agents for CTC detection
(Nima et al., 2014).
Although nanomethods are certainly capable of identifying
stem-like CTCs through surface stem cell markers, there is
a lack of nanomethods capable of capturing individual stem-
like CTCs with a high sensitivity. Because none of these
stem cell markers can be used exclusively to isolate CTCs in
every type of tumor, a combination of multitype antibodies
might help to specifically target CTCs. In addition, newer
isolation and detection nanotechnologies such as nanostructured
substrates and/or the incorporation of microfluidics devices
might achieve that level of sensitivity. Another critical need is the
development of nanotherapeutics for the stem-like CTCs. Beyond
their highly sensitive nano–bio interactions, drug carriers with
nanotechnologies may be potentially developed for the delivery
of various anticancer therapeutic agents to kill stem-like CTCs.
Other Nanotechnologies in CTC
Detection
A new SERS nanoparticle system was proposed for the direct
detection of CTCs in the blood (Wu et al., 2015). The
hydrodynamic diameter was determined to be 21 nm for SERS
nanoparticles. Under the optimized experimental conditions,
these SERS nanoparticles exhibited excellent specificity and high
sensitivity for the direct detection of cancer cells in rabbit blood.
The limit of detection (LOD) was 5 cells/mL, and a good linear
relationship was obtained between the SERS intensity and the
concentration of cancer cells in the range of 5–500 cells/mL,
which demonstrates that the SERS nanoparticles can be used for
the quantitative analysis of cancer cells in the blood. Overall,
although further testing of clinical blood samples is necessary,
SERS nanoparticles are promising for use in the direct detection
of CTCs in blood with excellent specificity and high sensitivity.
Carbon nanotubes have remarkable electronic properties and
have been applied for the electric detection of cancer cells
in the blood. Yang et al. (2014) demonstrated a quantitative
CNT-based sensor for direct detection of cancer cells in whole
blood using real-time electrical impedance sensing. Multi-walled
CNTs (MWCNTs) are used to increase the surface area and
electrical conductivity of sensors. The binding of tumor cells to
EpCAM antibodies causes increased electron-transfer resistance.
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The detection limit of the proposed system for the target
cancer cells is at a minimum concentration of 10 cells/mL
in whole blood samples. This method, via the simple process
of fabricating the sensors, accurate structural control over the
electrode surfaces, and high sensitivity and specificity for the
target cells, provides a promising platform for the early diagnosis
of cancer. In addition, Banerjee et al. (2015) reported a non-
invasive strategy for isolating cancer cells by autonomously
propelled CNT microrockets. This designed microrocket had the
ability to rapidly target (∼5 min) and efficiently capture (∼85%)
TfR+ cancer cells coming from an artificial CTC-like suspension,
then it can also function as a magnetic isolation platform to
capture cells from peripheral blood cells following high resolution
imaging. As a result, it may provide an approach for the rapid and
efficient extraction of CTCs.
CONCLUSION AND PROSPECTS
Cancer stem cells are believed to be responsible for tumor
relapse and metastasis, and stem cell properties are involved
in CTCs, known as stem-like CTCs, which contribute to seed
a distant metastasis. As CTC levels in the blood of patients
can allow for the early detection of cancer and act as a
prognostic indicator, the analyses of CTCs to screen patients for
the presence of metastatic disease is of great value in clinical
practice. Despite its clinical relevance, the isolation and detection
of CTCs can be quite challenging due to the extremely rare
presence of CTCs within the blood. To date, nanomaterials have
emerged with many excellent physical properties, including the
nanoscale size which is similar to ECM, large specific surface
area increasing the interaction with the target cells. What’s
more, nanomaterials can be functionalized with antibodies
to specifically recognize cells. Taking advantage of these
properties, increasing nanotechnologies have been developed as
a coordinator to improve the sensitivity and efficiency of CTC
isolation and detection and achieving the release of CTCs, such
as immunomagnetic nanobeads and nanostructure substrates.
Nanotechnologies are also incorporated in microfluidics devices
because it is more difficult to use one method for all types of
cancer. Even if the commercial success of CTC detection can be
achieved in the clinic, the survival or quality of life does not seem
to be improved. The major reason for this can be concluded as
the lack of anti-CTC therapy activities in these methods. That
is, patients should be undergo targeted CTC therapy to eliminate
CTCs in the peripheral blood after CTC detection.
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